BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15726096)

  • 1. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells.
    Roberts D; Schick J; Conway S; Biade S; Laub PB; Stevenson JP; Hamilton TC; O'Dwyer PJ; Johnson SW
    Br J Cancer; 2005 Mar; 92(6):1149-58. PubMed ID: 15726096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
    Holford J; Sharp SY; Murrer BA; Abrams M; Kelland LR
    Br J Cancer; 1998; 77(3):366-73. PubMed ID: 9472630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
    Helleman J; Burger H; Hamelers IH; Boersma AW; de Kroon AI; Stoter G; Nooter K
    Cancer Biol Ther; 2006 Aug; 5(8):943-9. PubMed ID: 16775422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).
    Holford J; Raynaud F; Murrer BA; Grimaldi K; Hartley JA; Abrams M; Kelland LR
    Anticancer Drug Des; 1998 Jan; 13(1):1-18. PubMed ID: 9474239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10.
    Varma RR; Hector SM; Clark K; Greco WR; Hawthorn L; Pendyala L
    Oncol Rep; 2005 Oct; 14(4):925-32. PubMed ID: 16142353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
    Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
    Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
    Sharp SY; Smith V; Hobbs S; Kelland LR
    Br J Cancer; 1998 Jul; 78(2):175-80. PubMed ID: 9683290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines.
    Holford J; Beale PJ; Boxall FE; Sharp SY; Kelland LR
    Eur J Cancer; 2000 Oct; 36(15):1984-90. PubMed ID: 11000581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
    Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
    Burger H; Zoumaro-Djayoon A; Boersma AW; Helleman J; Berns EM; Mathijssen RH; Loos WJ; Wiemer EA
    Br J Pharmacol; 2010 Feb; 159(4):898-908. PubMed ID: 20067471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
    Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
    Oyama Y; Shigeta S; Tokunaga H; Tsuji K; Ishibashi M; Shibuya Y; Shimada M; Yasuda J; Yaegashi N
    PLoS One; 2021; 16(6):e0251079. PubMed ID: 34161330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.
    Stukova M; Hall MD; Tsotsoros SD; Madigan JP; Farrell NP; Gottesman MM
    J Inorg Biochem; 2015 Aug; 149():45-8. PubMed ID: 26021697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
    Stronach EA; Alfraidi A; Rama N; Datler C; Studd JB; Agarwal R; Guney TG; Gourley C; Hennessy BT; Mills GB; Mai A; Brown R; Dina R; Gabra H
    Cancer Res; 2011 Jul; 71(13):4412-22. PubMed ID: 21571862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.